WT1 and acute myeloid leukemia: Although our data originate from a small unicentric group of patients, but with a relatively long follow-up (median of 12 months, range: 2–46), they suggest that WT1 expression assessed before allo-SCT may be a useful tool to identify AML patients who are at high risk of relapse.